Clinical trial
A Phase I, Open Label, Dose-Escalation, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR106 in Patients With Select Relapsed Advanced Malignancies (JIVAN)
NCT05861947 is registered in ClinicalTrials.gov with Aurigene Discovery Technologies Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Open Label, Dose-Escalation, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR106 in Patients With Select Relapsed Advanced Malignancies (JIVAN)
- Lead sponsor
- Aurigene Discovery Technologies Limited
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- August 26, 2023
- Completion date
- February 10, 2026
- Enrollment
- 21 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
advanced malignant neoplasm, colon cancer, esophagus cancer, gastric cancer, kidney cancer, non small cell lung cancer, relapse, urothelial carcinoma